Tivic Health Systems, Inc. (TIVC)
NASDAQ: TIVC · Real-Time Price · USD
3.880
+0.080 (2.11%)
At close: Jun 18, 2025, 4:00 PM
3.880
0.00 (0.00%)
Pre-market: Jun 20, 2025, 5:53 AM EDT
Company Description
Tivic Health Systems, Inc., a health tech company, develops and commercializes bioelectronic medicine.
Its primary product is ClearUP, a bioelectronic medicine for use in the treatment of sinus pain, pressure, and congestion.
The company sells its products through online retailers and commercial distributors, as well as its own website.
Its lead product candidate is Entolimod, a late-stage TLR5 agonist for use in the treatment of acute radiation syndrome.
In addition, the company markets its commercial product under the ClearUP Sinus Pain Relief brand name.
It also focusses on non-invasive vagus nerve stimulation. The company was incorporated in 2016 and is based in Fremont, California.
Tivic Health Systems, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Nov 11, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jennifer Ernst |
Contact Details
Address: 47685 Lakeview Blvd. Fremont, California 94538 United States | |
| Phone | (888) 276-6888 |
| Website | tivichealth.com |
Stock Details
| Ticker Symbol | TIVC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001787740 |
| CUSIP Number | 888705100 |
| ISIN Number | US8887052095 |
| Employer ID | 81-4016391 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Jennifer Ernst | Co-Founder, Chief Executive Officer and Director |
| Dr. Blake Gurfein Ph.D. | Chief Scientific Officer |
| Lisa G. Wolf | Interim Chief Financial Officer and Principal Financial and Principal Accounting Officer |
| Michael Kevin Handley | Chief Operating Officer and President of Tivic Biopharma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 6, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 2, 2025 | ARS | Filing |
| Jun 2, 2025 | DEF 14A | Other definitive proxy statements |
| May 23, 2025 | PRE 14A | Other preliminary proxy statements |
| May 22, 2025 | 8-K | Current Report |
| May 20, 2025 | 8-K | Current Report |
| May 15, 2025 | DRS | [Cover] Draft Registration Statement |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 14, 2025 | 8-K | Current Report |